Integer’s Pending Buyout Offers $127 Per Share as Sales Lag

Integer Holdings has agreed to be acquired by affiliates of Kohlberg Kravis Roberts for $127 in cash per eligible share at closing. The deal remains subject to conditions, including approval from holders of a majority of outstanding shares and regulatory clearances.

The acquisition has no financing condition, and the buyer has obtained equity and debt financing commitments. If completed, Integer would become a wholly owned subsidiary of the buyer and its shares would be delisted from the NYSE.

The pending deal comes as new-product adoption weighs on results. Integer’s second-quarter sales fell 2.6% year over year to $464.1 million, while adjusted earnings per share rose 3.2%. Lower production volumes also reduced fixed-cost absorption, and gross margin fell to 24.3% from 27.1% a year earlier.

Two new electrophysiology products contributed to a 2% decline in Cardio & Vascular sales, to $280.3 million. Cardiac Rhythm Management & Neuromodulation sales rose 1% to $173.7 million, despite softness in one neuromodulation product.

Integer has identified three recently launched products as a key drag on its 2026 outlook. Zacks said its consensus estimate for Integer’s 2026 earnings remained at $6.09 per share over the past 30 days. Its estimate for third-quarter sales is $457.3 million, down 2.2% from a year earlier.